AI Engines For more Details: Perplexity Kagi Labs You
Malaria Treatment: Amodiaquine is an antimalarial medication that is effective against Plasmodium falciparum malaria, which is the most deadly form of malaria. It works by interfering with the growth and reproduction of the malaria parasite within red blood cells.
Malaria Prevention: In addition to its use in treating acute malaria infections, amodiaquine may also be used for the prevention of malaria in individuals traveling to or residing in areas where malaria is endemic. It is often used in combination with other antimalarial drugs for this purpose.
Side Effects: Common side effects of amodiaquine may include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, and fatigue. Some individuals may also experience itching, rash, or other allergic reactions. These side effects are usually mild and temporary, but in some cases, they may be severe or persistent.
Hematologic Effects: Amodiaquine has been associated with rare but potentially serious adverse effects on the blood, including agranulocytosis (a severe reduction in white blood cell count), thrombocytopenia (a low platelet count), and hemolytic anemia (destruction of red blood cells). These effects may necessitate regular monitoring of blood counts during treatment.
Liver Toxicity: Amodiaquine has been associated with hepatotoxicity (liver toxicity), including elevated liver enzymes and, rarely, acute liver injury. Patients with pre-existing liver disease or a history of liver problems should be closely monitored during treatment with amodiaquine.
Neurologic Effects: In rare cases, amodiaquine has been associated with neurologic adverse effects, including seizures, confusion, and psychosis. Patients experiencing these symptoms should seek medical attention immediately.
Contraindications: Amodiaquine is contraindicated in patients with a history of hypersensitivity reactions to the drug or other 4-aminoquinoline compounds. It should also be used with caution in patients with a history of psychiatric disorders or epilepsy.
Drug Interactions: Amodiaquine may interact with other medications, including certain antimalarial drugs, antibiotics, antifungals, and medications metabolized by the liver enzymes CYP2C8 and CYP3A4. It's important to inform your healthcare provider about all medications you are taking before starting treatment with amodiaquine.
Pregnancy and Breastfeeding: The safety of amodiaquine in pregnant or breastfeeding women has not been well established. It should only be used during pregnancy or breastfeeding if the potential benefits outweigh the potential risks to the fetus or infant.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.2 | 0.6 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.5 | 0.36 |
| Allergies | 4.8 | 2.7 | 0.78 |
| Allergy to milk products | 2.3 | 1.6 | 0.44 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.9 | 5.2 | 0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.2 | 1.75 |
| Ankylosing spondylitis | 4.1 | 1.2 | 2.42 |
| Anorexia Nervosa | 1.3 | 2.4 | -0.85 |
| Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
| Asthma | 4.7 | 2.9 | 0.62 |
| Atherosclerosis | 2.4 | 1.1 | 1.18 |
| Atrial fibrillation | 3.2 | 2.2 | 0.45 |
| Autism | 9.3 | 8.4 | 0.11 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.5 | 2.5 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.3 | 1.8 | -5 |
| Carcinoma | 4.1 | 2 | 1.05 |
| Celiac Disease | 2.4 | 2 | 0.2 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 4.5 | 5.1 | -0.13 |
| Chronic Kidney Disease | 4.3 | 2.5 | 0.72 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.4 | 0.5 |
| Chronic Urticaria (Hives) | 1.7 | 1.4 | 0.21 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 2.8 | 1.3 | 1.15 |
| Colorectal Cancer | 7.6 | 2.8 | 1.71 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 2.7 | 2.3 | 0.17 |
| COVID-19 | 9.2 | 9.8 | -0.07 |
| Crohn's Disease | 9 | 5.2 | 0.73 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.8 | -0.5 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3 | 1.1 | 1.73 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 11.5 | 7.8 | 0.47 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 2.1 | -0.05 |
| Endometriosis | 3.5 | 1.4 | 1.5 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 4 | 2.7 | 0.48 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 1.8 | 1.06 |
| Functional constipation / chronic idiopathic constipation | 4.2 | 4.1 | 0.02 |
| gallstone disease (gsd) | 3.8 | 1.4 | 1.71 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.9 | 1.33 |
| Generalized anxiety disorder | 3.7 | 1.7 | 1.18 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.4 | 0.8 | 0.75 |
| Graves' disease | 1.3 | 2.7 | -1.08 |
| Gulf War Syndrome | 0.9 | 2.5 | -1.78 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.7 | 1.5 | 1.47 |
| Heart Failure | 4 | 1.8 | 1.22 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 1.6 | 0.3 | 4.33 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.6 | 0.33 |
| hyperglycemia | 2 | 2.1 | -0.05 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 5.1 | 3.9 | 0.31 |
| Hypothyroidism | 0.3 | 1 | -2.33 |
| Hypoxia | 3.6 | 0.3 | 11 |
| IgA nephropathy (IgAN) | 1.6 | 2.9 | -0.81 |
| Inflammatory Bowel Disease | 8.1 | 7.3 | 0.11 |
| Insomnia | 1.7 | 2.5 | -0.47 |
| Intelligence | 2 | 0.1 | 19 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 8.2 | 4.8 | 0.71 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 6.2 | 4.9 | 0.27 |
| Long COVID | 7 | 5.6 | 0.25 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.1 | 1.4 | -0.27 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.8 | 1.7 | -1.13 |
| ME/CFS without IBS | 2.1 | 1.9 | 0.11 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.8 | 0.9 | -0.13 |
| Metabolic Syndrome | 7.4 | 6.7 | 0.1 |
| Mood Disorders | 10.5 | 6.9 | 0.52 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 6.4 | 4.7 | 0.36 |
| Multiple system atrophy (MSA) | 1.4 | 0.4 | 2.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.6 | -4.33 |
| Neuropathy (all types) | 1 | 1.6 | -0.6 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.5 | 4.1 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 8.6 | 8.5 | 0.01 |
| obsessive-compulsive disorder | 4.7 | 4.1 | 0.15 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.9 | 5.8 | 0.36 |
| Polycystic ovary syndrome | 7 | 2.1 | 2.33 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.7 | -0.89 |
| Primary sclerosing cholangitis | 2 | 2.9 | -0.45 |
| Psoriasis | 2.8 | 3.4 | -0.21 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6 | 4 | 0.5 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 4.8 | 2.5 | 0.92 |
| scoliosis | 0.9 | 0.9 | |
| Sjögren syndrome | 1.6 | 3.1 | -0.94 |
| Sleep Apnea | 1.6 | 1.5 | 0.07 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 2 | |
| Stress / posttraumatic stress disorder | 3.5 | 3.4 | 0.03 |
| Systemic Lupus Erythematosus | 4 | 1.1 | 2.64 |
| Tic Disorder | 0.9 | 1.3 | -0.44 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 3.7 | 2.7 | 0.37 |
| Type 2 Diabetes | 8.6 | 7.9 | 0.09 |
| Ulcerative colitis | 6.2 | 5.6 | 0.11 |
| Unhealthy Ageing | 5.4 | 2.3 | 1.35 |
| Vitiligo | 1.9 | 1.5 | 0.27 |
